ERBB2 and breast cancer: Our findings show that STU reduces cell viability of HER2/neu+ breast and mammary tumor cells as well as HER2-inhibitor (trastuzumab and lapatinib) resistant HER2+ human breast cancer cells, which are dependent on HUNK as a pro-survival signaling molecule.